Kubota Vision Inc.01.27.22
Kubota Vision Inc. has achieved Quality Management System - ISO 13485:2016 certification for designing and developing ophthalmic medical devices.
“ISO 13485 certificate demonstrates our high standard quality system in the development of medical devices, and we are proud to be awarded this certificate. We are in the final stage of launching Kubota Glass, a wearable device for myopia management, and continue maximizing the company’s value and strategically enhancing our business,” said Ryo Kubota, M.D., Ph.D., chairman, president and CEO of Kubota Vision Inc.
ISO 13485 is an internationally recognized safety and quality standard for medical devices. Kubota Pharmaceutical group continues to pursue developing ophthalmic medical devices to satisfy unmet medical needs worldwide.
Kubota Vision Inc. is a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co. Ltd. committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide. The company is also developing a handheld OCT device for the monitoring of neovascular retinal diseases, to be used directly by patients, and a wearable device for myopia control.
“ISO 13485 certificate demonstrates our high standard quality system in the development of medical devices, and we are proud to be awarded this certificate. We are in the final stage of launching Kubota Glass, a wearable device for myopia management, and continue maximizing the company’s value and strategically enhancing our business,” said Ryo Kubota, M.D., Ph.D., chairman, president and CEO of Kubota Vision Inc.
ISO 13485 is an internationally recognized safety and quality standard for medical devices. Kubota Pharmaceutical group continues to pursue developing ophthalmic medical devices to satisfy unmet medical needs worldwide.
Kubota Vision Inc. is a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co. Ltd. committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide. The company is also developing a handheld OCT device for the monitoring of neovascular retinal diseases, to be used directly by patients, and a wearable device for myopia control.